Philip Scheltens (EAN Programme Committee; Professor of Cognitive Neurology and Director, Alzheimer Center, VU Medical Center, Amsterdam, The Netherlands) speaks to us following his Edouard Brown-Séquard Lecture during the Presidential Symposium entitled: The evolution of Alzheimer’s disease and dementia.
Questions
1. How have diagnostic criteria evolved in Alzheimer’s disease (AD)? (0:12)
2. What progress has been made in research to identify biomarkers in AD? (0:41)
3. What is your opinion on the concept of mild cognitive impairment to detect early AD? (1:16)
4. Why have so many clinical trials for AD failed? (1:50)
5. What new treatment modalities do you expect to emerge in the coming year? (2:32)
Speaker disclosure: Philip Scheltens has nothing to disclose in relation to this video interview.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
